Sepset

Sepset Biosciences, founded in 2016, is a pioneering company in the field of medical diagnostics, specifically focusing on the early detection of sepsis. The company operates in the healthcare sector, serving hospitals and medical professionals who are on the front lines of treating sepsis. Sepset's core product is a novel diagnostic assay that identifies a unique gene expression signature associated with sepsis, providing results within 1-2 hours. This rapid detection is crucial as it allows physicians to administer the appropriate treatment promptly, significantly reducing the risk of death associated with delayed treatment. Additionally, the test helps in identifying patients who are not at high risk, thereby reducing unnecessary use of potent antibiotics and mitigating the risk of antimicrobial resistance. Sepset's business model revolves around the commercialization of this diagnostic test, pending regulatory approvals, and aims to generate revenue through sales to healthcare institutions. The company also holds patents in Europe, China, and Hong Kong, with additional patents pending in other jurisdictions. Sepset's vision is to enhance patient survival rates, improve the quality of care, and optimize hospital spending by providing actionable information to healthcare providers.

Keywords: sepsis, diagnostic assay, gene expression, early detection, healthcare, hospitals, antimicrobial resistance, patient survival, medical diagnostics, regulatory approvals.